Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03294902
Other study ID # CIP-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 30, 2018
Est. completion date June 30, 2020

Study information

Verified date September 2020
Source Pedra Technology, PTE LTD
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Pedra Technologies' PedraTM device is a non-invasive, diagnostic device intended to measure foot perfusion by assessing blood flow. The PedraTM device comprises a compact instrument console connected to a sensor that is pasted onto the patient's foot during perfusion assessment. Through skin contact, the device is able to monitor tissue perfusion at depths of up to 7.5mm. The monitor console contains opto-electronic instrumentation including coherent infrared light sources, photo detectors, and display/control electronics. The sensor comprises passive fiber-optic conduits, which transfer infrared light from the console to the patient, and relays scattered light from the patient back to the console. The intensity of light emitted from the sensor is less than 3 mW, well within the safety envelope of Class I laser systems and comparable (or lower than) other commercially available devices such as laser Doppler systems. The sole point of contact with the patient is a layer of medical grade adhesive tape, which is used to paste the flat sensor onto intact skin.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date June 30, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 40 Years to 90 Years
Eligibility General Inclusion Criteria:

1. The patient is a male or non-pregnant female = 40 to 90 years of age

2. The patient is willing to comply with protocol-specified follow-up evaluations

3. The patient has been informed of the nature of the study, agrees to its provisions and has willingly provided written informed consent, approved by the appropriate Ethics Committee (EC)

Cohort Specific Inclusion Criteria:

Critical Limb Ischaemia Group Inclusion Criteria:

1. The subject is referred for a percutaneous peripheral revascularisation procedure on one of their lower limbs within 2 weeks of Baseline assessments.

2. Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels.

Peripheral Arterial Disease Group Inclusion Criteria:

1. The subject is referred for a percutaneous peripheral revascularisation procedure on one of their lower limbs within 2 weeks of Baseline assessments.

2. This subject must have a clinical diagnosis of claudication and duplex or CT-confirmed SFA or popliteal artery stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.

PAD-Free Group Inclusion Criteria:

1. The subject is recruited voluntarily

2. Absence of peripheral vascular disease determined by questionnaire and clinical review (triphasic signals on hand-held Doppler)

Exclusion Criteria:

1. Infusion of vasoactive medications within the past 24 hours

2. The presence of a known chronic history of anaemia (i.e. Hb <8g/dL)

3. Congestive heart failure defined by NYHA Classification 3 or 4

4. The absence of intact skin at suitable measurement sites on the foot.

5. The presence of invasive soft tissue infection in the toes spreading into the forefoot.

6. The presence of physical impediment to the method of measurements being completed (i.e. absent first two toes, extensive ulceration, excessive oedema, pressure dressings or heavy bandaging, etc.)

7. The presence of a non-salvageable foot or a Rutherford 6 wound.

8. The presence of other conditions, which in the opinion of the Investigator, may compromise the subject safety or comfort.

9. The presence of other conditions, which in the opinion of the Investigator, may compromise the accuracy of the data obtained.

10. The patient is a vulnerable or protected adult, or is unable to provide consent.

11. The patient is unable to comply with the measurement protocol.

12. Pregnant subjects

Study Design


Intervention

Device:
Pedra Tissue Perfusion Monitor
This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.

Locations

Country Name City State
United Kingdom Addenbrooke's Hospital, Department of Vascular Surgery Cambridge

Sponsors (1)

Lead Sponsor Collaborator
Pedra Technology, PTE LTD

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Baseline safety endpoint: The absence of immediately observable skin reaction (rash; local oedema, blistering of the skin) in = 90% of subjects after removal of the Pedra sensors. This observation assessment is completed by the physician post removal of the adhesive pads. It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin). Baseline visit: 30-60 minutes after pad removal
Primary During procedure safety endpoint: The absence of immediately observable skin reaction (rash; local oedema, blistering of the skin) in = 90% of subjects after removal of the Pedra sensors. This observation assessment is completed by the physician post removal of the adhesive pads. It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin). During procedure visit: 30-60 minutes after pad removal
Primary 36-hrs post-procedure/ discharge visit safety endpoint: The absence of immediately observable skin reaction (rash; local oedema, blistering of the skin) in = 90% of subjects after removal of the Pedra sensors. This observation assessment is completed by the physician post removal of the adhesive pads. It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin). 36-hrs post-procedure/ discharge visit: 30-60 minutes after pad removal
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A